Gilead Sciences
The firm reported strong revenue increases for its antibody-drug conjugate Trodelvy and its cell therapies Yescarta and Tecartus, offsetting losses outside oncology.
Gilead's Tecartus Gets EMA CHMP Recommendation in Advanced ALL
The committee reviewed data showing that 71 percent of patients on the CAR T-cell therapy had a complete remission or complete remission with incomplete hematological recovery.
NICE Recommends Novartis' Piqray, Gilead's Trodelvy for Certain Breast Cancer Patients in England
The institute was able to come to an agreement with the drugmakers to provide these therapies at an undisclosed, discounted price.
European Commission Approves Gilead Sciences' Yescarta for Follicular Lymphoma Patients
The autologous CAR T-cell therapy is now available in Europe as a fourth-line option for relapsed or refractory follicular lymphoma patients.
FDA Approves Bristol Myers Squibb's Breyanzi for Second-Line Lymphoma Patients
The autologous CD19-directed CAR T-cell therapy now competes with Gilead Sciences' Yescarta in the second-line large B-cell lymphoma setting.